Natera Inc.
Natera Announces Strong Second Quarter 2025 Financial Results and Raises Outlook
Summary
Natera, Inc. reported its financial results for the second quarter of 2025, showing a 32.2% increase in total revenues to $546.6 million compared to the same period last year. The company processed approximately 853,100 tests, a 12.2% increase. Natera also raised its 2025 annual revenue outlook by $80 million, citing record growth in Signatera and continued strength in its women's health and organ health product lines. The company processed a gross margin of 63.4%, up from 58.8% in the second quarter of 2024.
Profitelligence Alerts
Get alerts for NTRA
Be first to know when Natera Inc. files with the SEC.
Filing Categories
Exhibits (2)
Advertisement
About Natera Inc.
Natera Inc., a leading player in the life sciences and diagnostics industry, specializes in developing cell-free DNA testing technologies. This biotechnological firm primarily focuses on non-invasive genetic testing, assisting in maternal-fetal medicine through the screening of high-risk pregnancies with its flagship product, Panorama. In addition to prenatal screening, Natera offers genetic solutions for oncology and organ health, providing critical insights through its comprehensive suite of products. These offerings are especially significant in cancer diagnostics, where Natera's technology helps in early detection, monitoring, and guiding treatment options. The company's innovative approach to DNA analysis enables the identification of genetic conditions and the monitoring of health trends with precision and ease, impacting healthcare providers, patients, and researchers. With its headquarters in San Carlos, California, Natera Inc. is at the forefront of genetic testing advancements, playing a pivotal role in personalizing medicine and revolutionizing patient care by enhancing early diagnosis capabilities and improving clinical outcomes.
Official SEC Documents
Advertisement